Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES).

ABSTRACT: The release of GA (mitochondrial glutaminase) from neurons following acute ischaemia or during chronic neurodegenerative diseases may contribute to the propagation of glutamate excitotoxicity. Thus an inhibitor that selectively inactivates the released GA may limit the accumulation of excess glutamate and minimize the loss of neurological function that accompanies brain injury. The present study examines the mechanism of inactivation of rat KGA (kidney GA isoform) by the small-molecule inhibitor BPTES [bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide]. BPTES is a potent inhibitor of KGA, but not of the liver GA isoform, glutamate dehydrogenase or gamma-glutamyl transpeptidase. Kinetic studies indicate that, with respect to glutamine, BPTES has a K(i) of approx. 3 microM. Moreover, these studies suggest that BPTES inhibits the allosteric activation caused by phosphate binding and promotes the formation of an inactive complex. Gel-filtration chromatography and sedimentation-velocity analysis were used to examine the effect of BPTES on the phosphate-dependent oligomerization of KGA. This established that BPTES prevents the formation of large phosphate-induced oligomers and instead promotes the formation of a single oligomeric species with distinct physical properties. Sedimentation-equilibrium studies determined that the oligomer produced by BPTES is a stable tetramer. Taken together, the present work indicates that BPTES is a unique and potent inhibitor of rat KGA and elucidates a novel mechanism of inactivation.

SUBMITTER: Robinson MM

PROVIDER: S-EPMC2049044 | biostudies-other | 2007 Sep

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

Design, synthesis, and pharmacological evaluation of bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide 3 (BPTES) analogs as glutaminase inhibitors.

Project description:Bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES) is a potent and selective allosteric inhibitor of kidney-type glutaminase (GLS) that has served as a molecular probe to determine the therapeutic potential of GLS inhibition. In an attempt to identify more potent GLS inhibitors with improved drug-like molecular properties, a series of BPTES analogs were synthesized and evaluated. Our structure-activity relationship (SAR) studies revealed that some truncated analogs retained the potency of BPTES, presenting an opportunity to improve its aqueous solubility. One of the analogs, N-(5-{2-[2-(5-amino-[1,3,4]thiadiazol-2-yl)-ethylsulfanyl]-ethyl}-[1,3,4]thiadiazol-2-yl)-2-phenyl-acetamide 6, exhibited similar potency and better solubility relative to BPTES and attenuated the growth of P493 human lymphoma B cells in vitro as well as in a mouse xenograft model.

| S-EPMC3539823 | biostudies-literature

Structural basis for the active site inhibition mechanism of human kidney-type glutaminase (KGA).

Project description:Glutaminase is a metabolic enzyme responsible for glutaminolysis, a process harnessed by cancer cells to feed their accelerated growth and proliferation. Among the glutaminase isoforms, human kidney-type glutaminase (KGA) is often upregulated in cancer and is thus touted as an attractive drug target. Here we report the active site inhibition mechanism of KGA through the crystal structure of the catalytic domain of KGA (cKGA) in complex with 6-diazo-5-oxo-L-norleucine (DON), a substrate analogue of glutamine. DON covalently binds with the active site Ser286 and interacts with residues such as Tyr249, Asn335, Glu381, Asn388, Tyr414, Tyr466 and Val484. The nucleophilic attack of Ser286 sidechain on DON releases the diazo group (N2) from the inhibitor and results in the formation of an enzyme-inhibitor complex. Mutational studies confirmed the key role of these residues in the activity of KGA. This study will be important in the development of KGA active site inhibitors for therapeutic interventions.

| S-EPMC4929687 | biostudies-literature

1,2-Bis[1-(3-methyl-sulfanyl-1,2,4-triazin-5-yl)ethyl-idene]diazane.

Project description:The mol-ecule of the title compound, C(12)H(14)N(8)S(2), has an N-N gauche conformation. The triazine rings are nearly coplanar with respect to the imide bonds [C-C-C-N torsion angles = -15.3 (3) and -15.8 (3)°] and they are twisted by 77.88 (7)°. The overall conformation of the mol-ecule is stabilized by intra-molecular C-H⋯N hydrogen bonding. The mol-ecular packing is influenced by π-π inter-actions of the triazine systems with a shortest centroid-centroid separation of 3.5242 (12) Å.

| S-EPMC2977495 | biostudies-literature

Bis[3-ethyl-4-(4-methoxy-phen-yl)-5-(2-pyrid-yl)-4H-1,2,4-triazole-κN,N]bis-(perchlorato-κO)copper(II) acetonitrile disolvate.

Project description:In the title compound, [Cu(ClO(4))(2)(C(16)H(16)N(4)O)(2)]·2CH(3)CN, the Cu(II) atom, located on an inversion center, is in a tetra-gonally distorted octa-hedral environment, coordinated by four N atoms of two bidentate 3-ethyl-4-(4-methoxy-phen-yl)-5-(2-pyrid-yl)-4H-1,2,4-triazole ligands in equatorial positions and by the O atoms of two perchlorate groups in axial positions. The long axial Cu-O bond of 2.4743 (17) Å is the result of the Jahn-Teller effect.

| S-EPMC2961222 | biostudies-literature

Structural basis for exploring the allosteric inhibition of human kidney type glutaminase.

Project description:Cancer cells employ glutaminolysis to provide a source of intermediates for their upregulated biosynthetic needs. Glutaminase, which catalyzes the conversion of glutamine to glutamate, is gaining increasing attention as a potential drug target. Small-molecule inhibitors such as BPTES and CB-839, which target the allosteric site of glutaminase with high specificity, demonstrate immense promise as anti-tumor drugs. Here, we report the study of a new BPTES analog, N,N'-(5,5'-(trans-cyclohexane-1,3-diyl)bis(1,3,4-tiadiazole-5,2-diyl))bis(2-phenylacetamide) (trans-CBTBP), and compared its inhibitory effect against that of CB-839 and BPTES. We show that CB-839 has a 30- and 50-fold lower IC50 than trans-CBTBP and BPTES, respectively. To explore the structural basis for the differences in their inhibitory efficacy, we solved the complex structures of cKGA with 1S, 3S-CBTBP and CB-839. We found that CB-839 produces a greater degree of interaction with cKGA than 1S, 3S-CBTBP or BPTES. The results of this study will facilitate the rational design of new KGA inhibitors to better treat glutamine-addicted cancers.

| S-EPMC5295402 | biostudies-literature

4,4'-Bis(1,2,4-triazol-1-ylmeth-yl)biphen-yl.

Project description:In the title compound, C(18)H(16)N(6), the complete mol-ecule is generated by crystallographic inversion symmetry. The dihedral angle between the benzene and triazole rings is 84.1?(3)°. The crystal structure is stabilized by weak C-H?N hydrogen bonds.

| S-EPMC2970468 | biostudies-literature

Bis[?-1,2-bis-(1,2,4-triazol-4-yl)ethane]bis-[diiodidozinc(II)].

Project description:In the title dinuclear complex, [Zn(2)I(4)(C(6)H(8)N(6))(2)], two Zn(II )atoms are bridged by two 1,2-bis-(1,2,4-triazol-4-yl)ethane (btre) ligands, forming a centrosymmetric metallacycle. The coordination geometry of the Zn(II) ion is distorted tetra-hedral with the coordination sphere formed by two N atoms from the triazole rings of two symmetry-related btre ligands and two iodide ligands.

| S-EPMC2979062 | biostudies-literature

Bis[?-3-ethyl-4-phenyl-5-(2-pyrid-yl)-4H-1,2,4-triazole]bis-[dichloridocopper(II)].

Project description:The asymmetric unit of the title compound, [Cu(2)Cl(4)(C(15)H(14)N(4))(2)], contains two halves of two centrosymmetric dinuclear mol-ecules, A and B. The conformations of the two crystallographically independent mol-ecules are slightly different: in A, the Cu?Cu separation is 4.174?(9)?Å and the dihedral angle between the triazole and phenyl rings is 74.23?(11)°; these values are 4.137?(9)?Å and 68.58?(13)°, respectively, in B. In each mol-ecule, the copper(II) ions have a distorted trigonal-bipyramidal coordination geometry with a CuCl(2)NN'N'' chromophore. The crystal packing exhibits weak inter-molecular C-H?Cl inter-actions.

| S-EPMC2967870 | biostudies-other

Bis(4H-1,2,4-triazol-3-yl)disulfane.

Project description:The title compound, C(4)H(4)N(6)S(2), was synthesized by the reaction of 3-mercapto-1H-1,2,4-triazole with sodium hydrox-ide in ethanol. The mol-ecule possesses a crystallographically imposed twofold axis. Inter-molecular N-H⋯N hydrogen bonds link the mol-ecules into chains along the c axis.

| S-EPMC2915304 | biostudies-literature

Poly[[diaqua-{N-[1-(3-pyrid-yl)ethyl-idene]-4H-1,2,4-triazol-4-amine}zinc(II)] bis-(perchlorate)].

Project description:In the title compound, {[Zn(C(9)H(9)N(5))(2)(H(2)O)(2)](ClO(4))(2)}(n), the Zn(II) ion lies on an inversion center and is coordinated by two triazolyl N atoms and two pyridyl N atoms from four symmetry-related N-1-(3-pyrid-yl)ethyl-idene-4H-1,2,4-triazol-4-amine (L) ligands and two O atoms from coordinated water mol-ecules in a slightly distorted octa-hedral environment. Each L ligand bridges symmetry-related Zn(II) ions, forming a two-dimensional layer with a (4,4) grid. In the crystal structure, inter-molecular O-H⋯O hydrogen bonds connect perchlorate counter-anions to the layers.

| S-EPMC2977576 | biostudies-literature

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data